The stock of Moleculin Biotech Inc (NASDAQ: MBRX) has increased by 5.86 when compared to last closing price of 0.3.Moleculin Biotech Inc (NASDAQ: MBRX)’s stock price has plunge by 5.86relation to previous closing price of 0.3. Despite this, the company has seen a gain of 5.30% in its stock price over the last five trading days. globenewswire.com reported 2025-06-20 that HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the pricing of a public offering consisting of 16,080,000 shares of common stock (or pre-funded warrants in lieu thereof) and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying Series E warrants of $0.37. The Series E warrants will have an exercise price of $0.37 per share, are exercisable upon stockholder approval, and will expire five years following the initial exercise date.
Is It Worth Investing in Moleculin Biotech Inc (NASDAQ: MBRX) Right Now?
Moleculin Biotech Inc (NASDAQ: MBRX) has a higher price-to-earnings ratio of N/Ax compared to its average ratio, The 36-month beta value for MBRX is at 1.38. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price suggested by analysts for MBRX is N/A, which is -$1929993.0 below the current market price. The public float for MBRX is 21.99M, and currently, shorts hold a 8.79% of that float. The average trading volume for MBRX on July 01, 2025 was 1.93M shares.
MBRX’s Market Performance
MBRX’s stock has seen a 5.30% increase for the week, with a -63.26% drop in the past month and a -67.17% fall in the past quarter. The volatility ratio for the week is 15.48%, and the volatility levels for the past 30 days are at 13.28% for Moleculin Biotech Inc The simple moving average for the past 20 days is -39.32% for MBRX’s stock, with a -80.00% simple moving average for the past 200 days.
Analysts’ Opinion of MBRX
Many brokerage firms have already submitted their reports for MBRX stocks, with H.C. Wainwright repeating the rating for MBRX by listing it as a “Buy.” The predicted price for MBRX in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on June 09, 2025 of the current year 2025.
Maxim Group, on the other hand, stated in their research note that they expect to see MBRX reach a price target of N/A. The rating they have provided for MBRX stocks is “Hold” according to the report published on February 12th, 2025.
Oppenheimer gave a rating of “Outperform” to MBRX, setting the target price at $14 in the report published on July 18th of the previous year.
MBRX Trading at -60.31% from the 50-Day Moving Average
After a stumble in the market that brought MBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.21% of loss for the given period.
Volatility was left at 13.28%, however, over the last 30 days, the volatility rate increased by 15.48%, as shares sank -65.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -64.01% lower at present.
During the last 5 trading sessions, MBRX rose by +3.76%, which changed the moving average for the period of 200-days by -86.88% in comparison to the 20-day moving average, which settled at $0.5267. In addition, Moleculin Biotech Inc saw -90.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MBRX starting from Foster Jonathan P., who purchase 270,270 shares at the price of $0.37 back on Jun 23 ’25. After this action, Foster Jonathan P. now owns 287,587 shares of Moleculin Biotech Inc, valued at $100,000 using the latest closing price.
KLEMP WALTER V, the CEO and President of Moleculin Biotech Inc, purchase 675,675 shares at $0.37 during a trade that took place back on Jun 23 ’25, which means that KLEMP WALTER V is holding 743,607 shares at $250,000 based on the most recent closing price.
Stock Fundamentals for MBRX
Current profitability levels for the company are sitting at:
- N/A for the present operating margin
- N/A for the gross margin
The net margin for Moleculin Biotech Inc stands at N/A. The total capital return value is set at -1.84. Equity return is now at value -214.79, with -89.59 for asset returns.
Based on Moleculin Biotech Inc (MBRX), the company’s capital structure generated 0.89 points at debt to capital in total, while cash flow to debt ratio is standing at -66.59. The debt to equity ratio resting at 7.76. The interest coverage ratio of the stock is N/A.
Currently, EBITDA for the company is -21.64 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of N/A. The receivables turnover for the company is N/Afor trailing twelve months and the total asset turnover is N/A. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.
Conclusion
In conclusion, Moleculin Biotech Inc (MBRX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
